title: Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
abstract: Tigecycline In-vitro Surveillance in Taiwan (TIST), initiated in 2006, is a nationwide surveillance programme designed to monitor longitudinally the in-vitro activity of tigecycline against commonly encountered resistant bacteria. This study compared the in-vitro activity of tigecycline against clinical isolates of resistant Gram-negative bacteria determined by the broth microdilution and Etest methods. A total of 622 isolates were collected from patients treated at 20 teaching hospitals. Tigecycline had excellent in-vitro activity against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (N = 275) with MIC(90) 0.5 microg/mL and a 99.6% susceptibility rate, and also against ESBL-producing Klebsiella pneumoniae (N = 324) with MIC(90) 2 microg/mL and a 98.5% susceptibility rate. For ESBL-producing Proteus mirabilis (N = 15) the MIC(90) was 4 microg/mL with a 73.3% susceptibility rate. For ESBL-producing Klebsiella oxytoca (N = 8) the MIC(50) and MIC(90) were 0.5 and 1 microg/mL, respectively, with a 100% susceptibility rate. Limited agreement (<80%) was found between the broth microdilution and the Etest methods when determining the in-vitro activity of tigecycline against ESBL- producing K. pneumoniae and K. oxytoca.
authors.affiliation: Department of Internal Medicine, Lotung Poh-Ai Hospital, Yilan, Taiwan.
authors.forename: Chin-Te
authors.initials: CT
authors.lastname: Lu
authors.forename: Yin-Ching
authors.initials: YC
authors.lastname: Chuang
authors.forename: Wu
authors.initials: W
authors.lastname: Sun
authors.forename: Yung-Ching
authors.initials: YC
authors.lastname: Liu
authors.forename: Yu-Jen
authors.initials: YJ
authors.lastname: Cheng
authors.forename: Po-Liang
authors.initials: PL
authors.lastname: Lu
authors.forename: Chih-Ming
authors.initials: CM
authors.lastname: Chen
authors.forename: Gwo-Jong
authors.initials: GJ
authors.lastname: Hsu
authors.forename: Tsrang-Neng
authors.initials: TN
authors.lastname: Jang
authors.forename: Chun-Ming
authors.initials: CM
authors.lastname: Lee
authors.forename: Ping-Cherng
authors.initials: PC
authors.lastname: Chiang
authors.forename: Zhi-Yuan
authors.initials: ZY
authors.lastname: Shi
authors.forename: Lih-Shinn
authors.initials: LS
authors.lastname: Wang
authors.forename: Hsiang-Chi
authors.initials: HC
authors.lastname: Kung
authors.forename: Hsiu-Chen
authors.initials: HC
authors.lastname: Lin
authors.forename: Chun-Hsing
authors.initials: CH
authors.lastname: Liao
authors.forename: Jien-Wei
authors.initials: JW
authors.lastname: Liu
authors.forename: Cheng-Hua
authors.initials: CH
authors.lastname: Huang
authors.forename: Shih-Ming
authors.initials: SM
authors.lastname: Tsao
authors.forename: Po-Ren
authors.initials: PR
authors.lastname: Hsueh
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification*; D004756:Enterobacteriaceae Infections / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D013624:Taiwan; D000078304:Tigecycline; D001618:beta-Lactamases / Q000096:biosynthesis*
chemical_list: D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D001618:beta-Lactamases; D008911:Minocycline